Observational studyIn vivo (Athens, Greece)
Integrated Evaluation of Inflammatory, Nutritional, and Sarcopenia Markers to Predict Survival in Metastatic Breast Cancer Patients.
Observational study in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Predicting the prognosis of breast cancer patients by using pan-immune-inflammation value: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Sarcopenia as a prognostic indicator in colorectal cancer: an updated meta-analysis.Frontiers in oncology · 2023Pooled it
- Clinical utility of the pan-immune-inflammation value in breast cancer patients.Frontiers in oncology · 2023Pooled it
- Prognostic role of the Glasgow prognostic score and modified Glasgow prognostic score in patients with renal cell carcinoma undergoing immunotherapy: a meta-analysis.Clinics (Sao Paulo, Brazil) · 2026Article
- Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- Modified systemic immune-inflammatory index, modified systemic inflammatory response index and hemoglobin-albumin-lymphocyte-platelet score may serve as markers for evaluating the efficacy of neoadjuvant therapy in breast cancer patients.Frontiers in oncology · 2026Article
- The impact of sarcopenia on short-term efficacy, toxic and adverse reactions, and prognosis in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy.Frontiers in nutrition · 2026Article
- Prognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study.Gland surgery · 2025Article
- PIV and PILE scores predict the clinical outcome in patients with metastatic breast cancer treated with CDK4/6 inhibitors.International journal of clinical oncology · 2025Article
- Article
- Prognostic Importance of Panimmune-Inflammation Value and PILE Scores in Non-Metastatic Luminal A Breast Cancer.Breast care (Basel, Switzerland) · 2025Article
- Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy.Frontiers in nutrition · 2025Article
- Disulfidptosis-related lncRNA signature to assess the immune microenvironment and drug sensitivity in acute myeloid leukemia.Scientific reports · 2024Article
- Genetic overlap between breast cancer and sarcopenia: exploring the prognostic implications of SLC38A1 gene expression.BMC cancer · 2024Article
- Article
- Combined influence of nutritional and inflammatory status and breast cancer: findings from the NHANES.BMC public health · 2024Article
- Pretreatment Sarcopenia and MRI-Based Radiomics to Predict the Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Bioengineering (Basel, Switzerland) · 2024Article
- The role of nutrition-based index in predicting survival of breast cancer patients: A systematic review and meta-analysis.Heliyon · 2024Article
- Diagnostic Value of Nutritional Risk Index and Other Indices for Predicting Sarcopenia in the Middle-Aged and Elderly Population of China Without Cancer: A ROC Curve Analysis.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe prognosis of a cancer patient is influenced by the tumor-related factors, as well as by various patient-related factors. We evaluated the association between inflammatory and nutritional factors and their outcomes, including the prognosis and therapeutic course, in patients with metastatic breast cancer. PATIENTS AND
methodsIn this observational retrospective study, we evaluated 35 patients. The inflammatory and nutritional markers before systemic therapy included the lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammatory index (SII), systemic inflammatory response index (SIRI), pan-immuno-inflammatory values (PIV), prognostic nutritional index (PNI), Glasgow prognostic score (GPS), and psoas muscle index (PMI).
resultsTriple-negative, low PNI, and GPS 2 were correlated with worse overall survival in the univariable analysis. The GPS was the only independent predictor of overall survival [hazard ratio=5.85, 95% confidence interval=1.15-29.68, p<0.01]. The time to treatment failure of first-line therapy in patients with GPS 2 was significantly shorter than that in patients with GPS 0/1 (p<0.01).
conclusionThe GPS was an independent predictive marker for overall survival in patients with metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.